Japanese recommendation moves alogliptin closer to the market
This article was originally published in Scrip
Executive Summary
An advisory committee to Japan's ministry of health, labour and welfare has recommended for approval Takeda's oral antidiabetic, alogliptin. The positive opinion moves the DPP-4 inhibitor closer to what is likely to be its first market, following the delays in the US last year. Alogliptin has yet to be filed in Europe.
You may also be interested in...
Asia Deal Watch: Fujifilm Affiliate Out-Licenses Antifungal Candidate To Canada’s Appili
Novel antifungal T-2307, discovered by FUJIFILM Toyama, works by selectively disrupting mitochondrial function. Excelra and Maruho team up to repurpose existing drugs.
Asahi Paying $1.3bn For One-Product Veloxis
Diversified Japanese giant to launch tender for Danish transplant drug specialist as it looks to build US operations for health care business. Lundbeck and Novo Nordisk among investors that will see an exit.
Ebb TIDES As Takeda’s Dengue Contender Weaker At 18 Months
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: